The study of bioequivalence of twо ezetimib drugs after single oral administration in healthy volunteers
- Authors: Tolkacheva V.V.1, Malaya I.P.2, Bagmanova N.K.1, Kobalava Z.D.1
-
Affiliations:
- People’s Friendship University of Russia
- Ascent CRS
- Issue: Vol 21, No 1 (2019)
- Pages: 87-91
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/96905
- DOI: https://doi.org/10.26442/20751753.2019.1.190205
- ID: 96905
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Veronika V. Tolkacheva
People’s Friendship University of Russia
Email: tolkachevav@mail.ru
D. Sci. (Med.), Associate Professor of the Department of Internal Medicine with Cardiology and Functional Diagnostics course in V.S.Moiseyev academy 6, Miklukho-Maklaya st., Moscow, 117198, Russian Federation
Irina P. Malaya
Ascent CRSCand. Sci. (Med.), medical director 4, 1, block Б, entrance 7, floor 7, office 717Б, Business Park Rumyantsevo, 22nd km of the Kievskoe highway, housing estate, Moscow, 108811, Russian Federation*
Nazilia Kh. Bagmanova
People’s Friendship University of RussiaCand. Sci. (Med.), Associate Professor of the Department of Internal Medicine with Cardiology and Functional Diagnostics Course in V.S.Moiseyev Academy 6, Miklukho-Maklaya st., Moscow, 117198, Russian Federation
Zhanna D. Kobalava
People’s Friendship University of RussiaD. Sci. (Med.), Prof., Head of the Department of Internal Medicine with Cardiology and Functional Diagnostics Course in V.S.Moiseyev Academy, People’s Friendship University of Russia, Head of the Department of Internal Medicine, Cardiology and Clinical Pharmacology 6, Miklukho-Maklaya st., Moscow, 117198, Russian Federation
References
- Baigent C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366 (9493): 1267-78.
- Van Heek M, France C.F, Compton D.S et al. In vivo metabolism-based discovery of a potent cholesterol-absorption inhibitor, SCH 58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63.
- Catapano A.L, Graham I, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37: 2999-3058.
- Cannon C.P, Blazing M.A, Giugliano R.P et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.
- Оценка биоэквивалентности лекарственных средств. Методические рекомендации. М.: ФГБУ «НЦЭСМП», 2011.
- Руководство по экспертизе лекарственных средств. Под ред. проф. А.Н.Миронова и др. М.: Гриф и К, 2013.
- Правила проведения исследований биоэквивалентности лекарственных препаратов в рамках Евразийского экономического союза, утвержденные решением №85 Совета Евразийской экономической комиссии от 3 ноября 2016 г. http://www.consultant.ru/ document/cons_doc_LAW_207405/ (accessed 01.03.2018).
- Migoya E.M, Bergman A, Hreniuk D et al. Bioequivalence of ezetimibe/simvastatin tablet and coadministration. Int J Clin Pharmacol Ther 2006; 44 (2): 83-92.
- FDA. Clinical Pharmacoogy and Biopharmaceutical Review(s), ZETIA (ezetimibe). Application No.: 21445. Dec. 27, 2001.
- Gagner C, Bays H, Weiss S.R et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolaemia. Am J Cardiol 2002; 90: 1084-91.
- Ballantyne C.M, Houri J, Notarbartolo A et al. Effect of ezetimib coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia. A prospective, randomized double-blinde trial. Circulation 2003; 107: 2409-15.
- Feldman T, Koren M, Insull W et al. Treatment of high risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain national cholesterol education programm adult treatment panel III low-density lipoprotein goals. Am J Cardiol 2004; 93: 1481-86.
- Ziajka P.E, Reis M, Kreul S, King H. Initial low-density lipoprotein response to stain therapy predicts subsequent low-density lipoprotein response to the addition o ezetimibe. Am J Cardiol 2004; 93: 779-80.
- Stroup J.S, Kane M.P, Busch R.S. The antilipidemic effects of ezetimibe in patients with diabetes mellitus. Diabetes Care 2003; 26: 2958-59.